Business Description
Inovio Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US45773H4092
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.51 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -17.4 | |||||
Beneish M-Score | -1.21 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -59.5 | |||||
3-Year EBITDA Growth Rate | 20.2 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 26 | |||||
3-Year Book Growth Rate | -44.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 22.35 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.35 | |||||
9-Day RSI | 44.78 | |||||
14-Day RSI | 37.95 | |||||
6-1 Month Momentum % | -25.28 | |||||
12-1 Month Momentum % | 27.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.45 | |||||
Quick Ratio | 4.45 | |||||
Cash Ratio | 4.18 | |||||
Days Sales Outstanding | 24.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.5 | |||||
Shareholder Yield % | -10.02 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -19783.11 | |||||
Net Margin % | -20547.47 | |||||
FCF Margin % | -18984.25 | |||||
ROE % | -98.72 | |||||
ROA % | -70.72 | |||||
ROIC % | -274.89 | |||||
3-Year ROIIC % | 14.95 | |||||
ROC (Joel Greenblatt) % | -833.81 | |||||
ROCE % | -89.93 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 219.23 | |||||
PB Ratio | 1.53 | |||||
Price-to-Tangible-Book | 1.53 | |||||
EV-to-EBIT | -0.42 | |||||
EV-to-EBITDA | -0.43 | |||||
EV-to-Revenue | 85.4 | |||||
EV-to-Forward-Revenue | 252.78 | |||||
EV-to-FCF | -0.45 | |||||
Price-to-Median-PS-Value | 6.95 | |||||
Price-to-Net-Current-Asset-Value | 1.84 | |||||
Price-to-Net-Cash | 2.01 | |||||
Earnings Yield (Greenblatt) % | -238.1 | |||||
FCF Yield % | -76.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Inovio Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 10.324 | ||
EPS (TTM) (MXN) | -88.67 | ||
Beta | 0.75 | ||
Volatility % | 92.38 | ||
14-Day RSI | 37.95 | ||
14-Day ATR (MXN) | 1.649895 | ||
20-Day SMA (MXN) | 113.0725 | ||
12-1 Month Momentum % | 27.6 | ||
52-Week Range (MXN) | 75 - 235 | ||
Shares Outstanding (Mil) | 25.96 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Inovio Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Inovio Pharmaceuticals Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Inovio Pharmaceuticals Inc Frequently Asked Questions
What is Inovio Pharmaceuticals Inc(MEX:INO)'s stock price today?
When is next earnings date of Inovio Pharmaceuticals Inc(MEX:INO)?
Does Inovio Pharmaceuticals Inc(MEX:INO) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |